36-month durability of ultrasound renal denervation for hypertension resistant to combination therapy in RADIANCE-HTN TRIO

Michael J. Bloch*, Ajay J. Kirtane, Michel Azizi, Felix Mahfoud, Jan Basile, Joost Daemen, Manish Saxena, Lisa Thackeray, Maureen McGuire, Lisa Claude, Roland E. Schmieder, Patric Kröpil, Johannes Stegbauer, Christian Rump, Michael Uder, Christian Ott, Jelena Lucic, Sebastian Ewen, Michael Böhm, Karl Philipp RommelKarl Fengler, Robert Höllriegel, Philipp Lurz, Cristina Elorz, Andrew John Marshall, Mohamad Faris, Robert Gerber, Richard D’Souza, Anil Joseph, Andrew S.P. Sharp, James Howard, Matthew Shun Shin, Neil Chapman, Justin Davies, David Beckett, Amit Patel, Sadat Ali Edroos, Nicholas Robinson, Sudha Ganesh Iyer, Jeremy Sayer, Scott Biedermann, Sandeep Aggarwal, Jonathan Williams, Courtney Walsh, Ronald Victor, Radoslaw Owczuk, Milosz J. Jaguszewski, Claudia de Haan, W. H. van Zwam, A. A. Kroon, RADIANCE-HTN Investigators

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Endovascular ultrasound renal denervation (uRDN) reduced blood pressure (BP) compared to sham at 2 months in patients with resistant hypertension in the multicenter, blinded, randomized, sham-controlled RADIANCE-HTN TRIO trial. This analysis evaluates longer-term outcomes of patients randomized to uRDN. Patients with resistant hypertension to a 3-drug combination pill were randomized to uRDN (n = 69) or sham (n = 67). From 2-5 months, patients followed a standardized anti-hypertensive medication (AHM) titration protocol. At 6 months, patients were unblinded and received AHM per standard of care. In the uRDN group, 71% (49/69) completed 36-month follow-up. Screening office BP was 159/103 on 3.9 AHM. Baseline office BP on the single-pill combination was 153/99 mmHg. At 36 months, office BP changed by -14.5 ± 26.1/-9.0 ± 14.8 mmHg from screening (p < 0.001 for both) and -8.0 ± 24.5/-5.0 ± 14.6 mmHg from baseline (p = 0.007; p = 0.022) on 3.7 AHM. The efficacy of uRDN was durable to 36 months in patients with resistant hypertension with no safety concerns. (Figure presented.)
Original languageEnglish
JournalHypertension Research
DOIs
Publication statusE-pub ahead of print - 1 Jan 2024

Keywords

  • blood pressure
  • Hypertension
  • renal denervation
  • ultrasound

Fingerprint

Dive into the research topics of '36-month durability of ultrasound renal denervation for hypertension resistant to combination therapy in RADIANCE-HTN TRIO'. Together they form a unique fingerprint.

Cite this